The investigation of clinical effects of repaglinide in diabetic patients over 65 years old

The investigation of clinical effects of repaglinide in diabetic patients over 65 years old - The clinical effects of repaglinide on elderly

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000007759

Enrollment

Registered

2012-05-20

Start date

2012-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes mellitus

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)a)diavetic patients with diet and exercise therapy over 8 weeks b)diavetic patients with diet, exercise therapy and arufa GI over 12weeks 2)6.9% <=HbA1c<=9.4% 3)age over 65 years old 4)patients with written informed consent

Exclusion criteria

Exclusion criteria: 1) aptients with severe ketosis:ketotic coma or precoma 2)severe infectious disease 3)liver dysfunction (more than 2.5 times of the upper normal limit in AST and ALT 4)kidney dysfunction: sCR>=2mg/dl 5)heart disease: heart failure (NYHAIII andIV unstable aigina, MI within 12months 6)diabetic complications: proliferative retinopathy or preproliferative retinopathy, severe nueropathy with need of treatment 7) severe and uncontrolable hypertension: systolic BP 180mmHg, or diastolic 110nnHg 8) alcholics: more than 2 large bottles of beer 9) makignancy 10) alergy for glimides and SUs 11) pregnant 12) patients with past prescription of lepagrinide 13) attending doctors decision

Design outcomes

Primary

Measure	Time frame
TC, LDL, HDK, TG, Blood glucose, CRP, ASST, ALT, gGTP	—

Secondary

Measure	Time frame
adverse events	—

Countries

Japan

Outcome results